Results 101 to 110 of about 50,591 (247)

Impact of anti‐VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta‐analysis

open access: yesActa Ophthalmologica, Volume 104, Issue 1, Page e1-e17, February 2026.
Abstract Purpose Retinopathy of prematurity (ROP) is a major cause of childhood blindness, and selecting the optimal treatment between anti‐vascular endothelial growth factor (anti‐VEGF) and laser therapy is crucial. Understanding their impact on key outcomes, particularly mortality, is essential for informed clinical decision‐making.
Wei‐De Wang   +10 more
wiley   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo   +8 more
wiley   +1 more source

LncRNA DANCR Activates p38/mTOR‐Mediated Autophagy via ANXA2 to Exacerbate Oxygen‐Induced Retinal Neovascularization in Mice

open access: yesThe FASEB Journal, Volume 40, Issue 1, 15 January 2026.
This study reveals that the long non‐coding RNA DANCR drives pathological retinal neovascularization in oxygen‐induced retinopathy via an ANXA2‐dependent p38/MAPK/mTOR autophagy pathway. In hypoxic endothelial cells and a murine OIR model, DANCR promotes angiogenesis.
Yini Wang, Jiale Bai, Shihong Zhao
wiley   +1 more source

Cystoid Macular Edema Associated with Oral Antineoplastic Agent S-1 in a Patient with Diabetic Retinopathy

open access: yesCase Reports in Ophthalmology, 2012
A 60-year-old man with neovascular glaucoma due to diabetic retinopathy received an intravitreal injection of 1.25 mg bevacizumab (IVB) followed by extensive panretinal photocoagulation in the right eye.
Tomomi Higashide   +2 more
doaj   +1 more source

Acrolein Promotes Retinal Inflammation Through Macrophage Chemotaxis by Inducing CCL2 Production From Müller Cells

open access: yesThe FASEB Journal, Volume 40, Issue 1, 15 January 2026.
Patients with proliferative diabetic retinopathy show elevated vitreous levels of the acrolein adduct FDP‐lys and CCL2. In rat Müller glial cells (TR‐MUL5), acrolein increases Ccl2 gene expression and CCL2 secretion and promotes macrophage migration.
Kanae Fukutsu   +4 more
wiley   +1 more source

Factors associated with visual recovery after sub-Tenon injection of triamcinolone acetonide in diabetic macular edema

open access: yesClinical Ophthalmology, 2012
Hiroko Kawashima, Kenichi Mizukawa, Junichi KiryuDepartment of Ophthalmology, Kawasaki Medical School, Okayama, JapanBackground: The purpose of this retrospective chart review was to evaluate factors associated with improvement of visual acuity after a ...
Kawashima H, Mizukawa K, Kiryu J
doaj  

Supplementary Material for: Interdigitation and Ellipsoid Zones Disruption Correlate with Visual Outcomes among Treatment-Naive Patients with Diabetic Macular Edema

open access: gold, 2021
Nardine Sharef   +8 more
openalex   +1 more source

Selective Laser Sintering 3D Printing of Drug‐Loaded Intravitreal Implants

open access: yesAdvanced Functional Materials, Volume 36, Issue 4, 12 January 2026.
Selective laser sintering enables the fabrication of biodegradable and biocompatible intravitreal implants with tunable microstructures for sustained drug delivery. By modulating laser scanning speed, the polymer matrix architecture is engineered to control the release kinetics of dexamethasone and riboflavin over several months. This approach offers a
Iria Seoane‐Viaño   +5 more
wiley   +1 more source

Continuous Suppression of Pathological Retinal and Choroidal Neovascularization in Cynomolgus Monkeys via Noninvasive Ophthalmic Delivery of a Novel Anti‐VEGFA Nanobody and Proprietary Penetratin Analog Formulation

open access: yesAdvanced Science, Volume 13, Issue 1, 5 January 2026.
Pathological retinal/choroidal neovascularization drives vision loss in DR and AMD. Current anti‐VEGF injections, while effective, require invasive, frequent administration. Pene/LQ015, is developed a novel topical anti‐VEGFA nanobody formulation achieving therapeutic intraocular levels through penetratin analog‐enhanced delivery.
Chong Chen   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy